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Focus Article
AAPT Diagnostic Criteria for Chronic Sickle Cell Disease
Pain
Carlton Dampier,* Tonya M. Palermo,y Deepika S. Darbari,z Kathryn Hassell,x Wally Smith,{
and William Zempskyk
*Emory University School of Medicine, Atlanta, Georgia.
y
Seattle Children’s Research Institute, Seattle, Washington.
z
Children’s National Medical Center, Washington, D.C.
x
University of Colorado School of Medicine, Aurora, Colorado.
{
Virginia Commonwealth University Health System, Richmond, Virginia.
k
Connecticut Children’s Medical Center, Hartford, Connecticut.

Abstract: Pain in sickle cell disease (SCD) is associated with increased morbidity, mortality, and high
health care costs. Although episodic acute pain is the hallmark of this disorder, there is an increasing
awareness that chronic pain is part of the pain experience of many older adolescents and adults. A
common set of criteria for classifying chronic pain associated with SCD would enhance SCD pain
research efforts in epidemiology, pain mechanisms, and clinical trials of pain management interventions, and ultimately improve clinical assessment and management. As part of the collaborative
effort between the Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks public-private partnership with the U.S. Food and Drug Administration and the
American Pain Society, the Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations
Opportunities and Networks-American Pain Society Pain Taxonomy initiative developed the outline
of an optimal diagnostic system for chronic pain conditions. Subsequently, a working group of experts in SCD pain was convened to generate core diagnostic criteria for chronic pain associated
with SCD. The working group synthesized available literature to provide evidence for the dimensions
of this disease-specific pain taxonomy. A single pain condition labeled chronic SCD pain was derived
with 3 modifiers reflecting different clinical features. Future systematic research is needed to evaluate
the feasibility, validity, and reliability of these criteria.
Perspective: An evidence-based classification system for chronic SCD pain was constructed for the
Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and
Networks-American Pain Society Pain Taxonomy initiative. Applying this taxonomy may improve
assessment and management of SCD pain and accelerate research on epidemiology, mechanisms,
and treatments for chronic SCD pain.
ª 2017 The Authors. Published by Elsevier Inc. on behalf of the American Pain Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Key words: Sickle cell disease, chronic pain, taxonomy, diagnostic criteria.
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ickle cell disease (SCD) encompasses a group of
related genetic disorders of hemoglobin structure,
and is the most common genetic blood disease
among individuals in North America. SCD most
commonly occurs in individuals whose ethnic origin is
from Africa, Middle East, Indian Subcontinent, Southern
Europe, South or Central America, or the Caribbean.35
The hallmark feature of SCD is recurrent episodes of
acute pain, presumably ischemic in origin, caused by a
remarkably complex process leading to obstruction of
blood flow in vulnerable tissue beds by sickled erythrocytes,72 typically referred to as a vaso-occlusive crisis.63
From the patient perspective, SCD pain is reportedly
worse than postoperative pain,16,32 as intense as cancer
pain,82 and has a negative effect on all aspects of the individual’s health-related quality of life.21,22 Recurrent
pain is the main reason for SCD-related hospitalization,
and drives annual health care costs of $1.1 billion.42 Having frequent or prolonged episodes of pain is a key predictor of morbidity and mortality.38,60,61 Although as yet
poorly studied, clinicians and researchers are increasingly
appreciating that for many adolescent and adult
patients with SCD these episodes of recurrent acute
pain occur in the context of ongoing persistent or
chronic pain.13,69
Mounting evidence shows that the burden of SCD pain
as well as pain-associated health care utilization increase
from childhood to adolescence and young adulthood.19,67,69,70 Diary studies show that children with
SCD report pain on 16 to 30% of days and pain
becomes more severe in adolescence as evidenced by a
marked increase in the use of opioids (57% of days in
youth ages 14–19 years old, but only 10–11% of days in
younger age groups).19,67 By adulthood, the prevalence
of pain continues to increase. For example, in the Pain
in Sickle Cell Epidemiology Study, a daily diary study of
232 adults with SCD, 55% of adult respondents
reported pain on more than half of the days and 29%
reported pain on 95% of days, suggesting a substantial
prevalence of chronic pain.69 Whereas most of these reported pain days were not described as ‘‘crisis’’ pain, a minority of pain days with more intense pain were
described as ‘‘crisis’’-related. The temporal overlap of
these ‘‘crisis’’ and non-‘‘crisis’’ pain days suggested some
individuals experienced a pattern of acute episodic
pain superimposed upon chronic pain.
Consistent with other pediatric chronic pain conditions, youth with SCD reporting pain on most days had
significantly greater functional disability, depressive
symptoms, and inpatient admissions for pain relative to
patients characterized as having episodic or no SCD
pain.68 Similarly, adults with frequent days of pain had
higher somatic symptom burden and were more likely
to be depressed or anxious.71
There are no existing consensus-based criteria for
chronic SCD pain from which to draw for deriving a
formal diagnostic classification. This lack of clarity in
what defines chronic SCD pain has hindered research efforts in understanding the epidemiology of chronic
SCD pain, mechanisms of chronic SCD pain, and in developing effective pain management interventions in this
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population. Chronic pain criteria on the basis of the
duration of pain persistence from an inciting event,
such as used for postoperative pain, is particularly problematic in a condition like SCD in which patterns of
frequent recurrent pain occur. The likely overlap of acute
and chronic pain suggested the potential utility of a
frequency-based criteria similar to the classification system of the International Classification of Headache Disorders,36 because of the similar episodic nature of
headache disorders compared with acute sickle pain
and the propensity for frequent headaches to become
chronic or daily.
To meet the need for an evidence-based chronic pain
classification system, the Analgesic, Anesthetic, and
Addiction Clinical Trial Translations Innovations Opportunities and Networks public-private partnership with
the U.S. Food and Drug Administration and the American
Pain Society collaborated to develop the Analgesic,
Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks-American Pain Society Pain Taxonomy (AAPT). The resultant pain taxonomy
framework developed through this initiative incorporates knowledge of biopsychosocial mechanisms and
classifies chronic pain conditions along 5 dimensions
including: 1) core diagnostic criteria, 2) common features, 3) common medical and psychiatric comorbidities,
4) neurobiological, psychological, and functional consequences, and 5) putative neurobiological and psychosocial mechanisms, risk factors, and protective factors.
This framework is comprehensively described in Fillingim
et al30 and further background concerning the AAPT
initiative is available in a series of additional review
articles.10,27,29,31,48,75,78,80
The aim of our working group on SCD pain was to
apply the AAPT framework to identify chronic pain condition(s) associated with SCD and to propose a diagnostic
classification system on the basis of the 5 dimensions of
the AAPT.

Methods
A 6-member interdisciplinary work group (WG) of clinicians and clinical scientists with expertise in SCD pain
and chronic pain across the lifespan was convened. The
WGs met during an AAPT consensus conference in July
2014 in Annapolis, Maryland. Before the meeting, relevant guidelines and literature on SCD pain was searched
and compiled to examine pain definitions, epidemiology, and risk factors. In particular, key review articles
proposing definitions or conceptualizations of chronic
SCD pain were identified (eg, Ballas,4 Ballas et al,5 and
Taylor et al73), and original research presenting data on
pain patterns and characteristics available from daily diary studies in the SCD population were reviewed.69 In
several teleconferences before the meeting, this literature was discussed and preliminary definitions of chronic
SCD pain were drafted.
The WG made the decision to not perform an exhaustive review of the literature. Systematic reviews conducted recently to inform the 2014 evidence-based report on
management of SCD84 reported little evidence related
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specifically to chronic pain of individuals with SCD. Thus,
the WG’s stance was that proposing another systematic
review was not anticipated to yield new findings. Rather,
the WG sought to identify key definitions, focusing discussion on significant items pertaining to defining
chronic pain in SCD. Background readings provided by
the AAPT steering committee relating to multiaxial diagnostic classification systems were also reviewed so that
the WG could apply this evidence-based framework to
chronic pain in SCD.
During the consensus conference, full details on the
AAPT framework were presented by the steering committee, and the WG developed an initial draft version that
contained 2 diagnostic categories for chronic SCD pain.
Each chronic pain WG presented their draft diagnostic
categories to the larger group allowing for additional opportunities to incorporate feedback to refine signs and
symptoms proposed in the classification system.
After the consensus meeting, the WG used the AAPT
background documents and conducted several teleconferences to further refine the draft diagnostic categories.
The WG cochairs (C.D. and T.M.P.) compiled literature to
support the diagnostic categories proposed. Because of
the lack of available evidence from the literature specifically on chronic pain in SCD to support 2 distinct diagnoses of chronic SCD pain, the WG members unanimously

AAPT Diagnostic Criteria for Chronic
Pain Associated With SCD (Chronic SCD Pain)

Table 1.

DIMENSION 1: CORE DIAGNOSTIC CRITERIA
1. Diagnosis of SCD confirmed by laboratory testing
2. Reports of ongoing pain present on most days over the past
6 months either in a single location or in multiple locations
3. Must display at least 1 sign:
 Palpation of the region of reported pain elicits focal pain or
tenderness
 Movement of the region of reported pain elicits focal pain
 Decreased range of motion or weakness in the region of reported
pain
 Evidence of skin ulcer in the region of reported pain
 Evidence of hepatobiliary or splenic imaging abnormalities (eg,
splenic infarct, chronic pancreatitis) consistent with the region of
reported pain
 Evidence of imaging abnormalities consistent with bone infarction
or avascular necrosis in the region of reported pain
4. There is no other diagnosis that better explains the signs and
symptoms
Chronic SCD pain diagnostic modifiers:
We propose 3 diagnostic modifiers to indicate subtypes of chronic SCD
pain.
1. Chronic SCD pain without contributory disease complications is
used if there is no evidence of contributory SCD complications on
the basis of either clinical signs (eg, presence of leg ulcers) or test
results (eg, imaging abnormalities)
2. Chronic SCD pain with contributory disease complications should
be used if there is evidence of contributory SCD complications on
the basis of clinical signs or test results
3. Chronic SCD pain with mixed pain types should be used if there is
evidence of contributory SCD complications (eg, avascular necrosis)
on the basis of clinical signs or test results and there is pain also
occurring in unrelated sites (eg, arms, back, chest, or abdominal
pain)

agreed to revise the draft categories to instead propose
a single diagnostic category of chronic SCD pain. In line
with the evidence-based recommendations for managing
chronic complications of SCD84 the WG proposed 3 subtypes of chronic SCD pain to account for the effect of
chronic complications of SCD on the experience of chronic
pain. The AAPTsteering committee provided the structure
for Table 1 and suggested terminology for all WGs to
apply. Revisions were made until all WG members agreed
on the wording of each of the signs and symptoms listed.

Results
Our proposed classification is for a single pain condition,
which we label chronic SCD pain, with 3 subtypes: 1)
chronic SCD pain without contributory disease complications, 2) chronic SCD pain with contributory disease complications, and 3) chronic SCD pain with mixed presentation.

Chronic SCD Pain
Dimension 1. Core Diagnostic Criteria of
Chronic SCD Pain
The AAPT criteria for chronic SCD pain are summarized
in Table 1. The history must include a diagnosis of SCD
confirmed by appropriate laboratory testing. Three diagnostic modifiers indicate subtypes of chronic SCD pain to
distinguish between the presence or absence of contributory disease complications as a source of chronic pain
(eg, leg ulcers, avascular necrosis) and a mixed presentation that includes pain in the presence of local contributory disease complications as well as pain also occurring
in other unrelated sites. Differential diagnosis includes
distinguishing between chronic SCD pain and other primary pain conditions with specific defined etiologies
that individuals with SCD may develop, such as migraine
headaches or autoimmune disorders (eg, lupus, rheumatoid arthritis).39,55,56 Previous research has shown that
patients are able to attribute pain to their SCD rather
than to other causes (eg, other injuries or illnesses) and
to distinguish crisis pain from noncrisis pain
(presumably ongoing chronic pain).19,69,82
Diagnosis of chronic SCD pain requires that, in addition to ongoing pain, the patient displays at least 1
sign of pain sensitivity on palpation or with movement
of the region of reported pain, decreased range of motion or weakness in the region of reported pain, or evidence of chronic disease complications (eg, skin ulcer,
splenic infarct, or bone infarction) associated with the region of reported pain.

Dimension 2. Common Features of
Chronic SCD Pain, Including
Epidemiology and Lifespan
Considerations
SCD pain is considered to be chronic SCD pain when such
pain is present on most days, and has occurred for at least
the previous 6 months. As noted, more than half of adult
patients with SCD report pain on more than half of days,
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and 29% report pain occurring almost daily. Similarly,
15% of adolescents, and 10% of young children with
SCD also report pain on most days lasting greater than
6 months.68 The daily use of opioids for pain management
in older children and adolescents, and in adults, is also reported, consistent with reports of very frequent or daily
pain.17,67 Pain in multiple locations is common20,32 with
an average of 3 or more sites of pain identified by
patients,50 most commonly extremities, back, and abdominal sites. Most patients describe their pain as constant,
continuous, or steady.82 Half of patients also describe/
report pain patterns that are intermittent, periodic, or
rhythmic.69,82 In one study, 90% of 145 adults with SCD
described their pain using at least some neuropathic
pain descriptors on a pain quality questionnaire.82 Unfortunately, only a few of these studies distinguished between acute and chronic pain, so additional data are
needed to identify features unique to chronic SCD pain.
Compared with those with infrequent episodic pain, children and adolescents with chronic SCD pain were seen
more often for pain management in acute care and hospital settings, reflecting the difficulties of treating combined acute and chronic pain.66
Individuals with SCD may experience pain originating
from complications in bone or associated structures, soft
tissues, and internal organs. Hepatic or splenic enlargement from accumulation of fluid and blood cells may
lead to chronic pain from capsular stretch or pericapsular infarction. Other pain symptoms related to disease
complications include pain at the site of ulcers that
occur in the skin and associated soft tissues on either
side of the ankles,53 and pain at the site of the humeral
or femoral heads from avascular necrosis.51,66 Although
uncommon in children, prevalence rates for leg ulcers in
adults with SCD range from 5 to 10%.43 Avascular necrosis can occur in older children, adolescents, and adults in
either the hip (femoral head) or shoulder (humeral
head) joint and is often bilateral (40–60%).1,47 The cooccurrence of shoulder and hip involvement is also
high. Similarly, persistent back pain from vertebral
collapse or fractures occurs in 2 to 5% of individuals
with SCD.65 These SCD complications create persistent
or irreversible injury and contribute to significant pain.
For example, in a study of adults with SCD, ulcers had
been present for a median of 10 months with a range
of 2 to 300 months.52

Dimension 3. Common Medical and
Psychiatric Comorbidities Associated
With Chronic SCD Pain
Clinical manifestations of SCD vary by frequency and
severity and are hypothesized to have differing pathophysiology. Natural history studies suggest that more
frequent acute vaso-occlusive pain and certain disease
characteristics (eg, presence of alpha thalassemia characterized by higher hematocrit, lower mean corpuscular
volume) are associated with osteonecrosis of the femoral
head.51 In contrast, other disease complications such as
leg ulcers are more strongly associated with intensity of
hemolysis41 than with frequency of acute vaso-
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occlusive pain. Frequent acute pain has also been associated with an increased risk of pulmonary hypertension
and subsequent cardiovascular disease,25 and with an
increased risk for acute chest syndrome and subsequent
chronic pulmonary disorders.59,77 Asthma has been
associated with an increased frequency of acute pain
and chest syndrome episodes.26 Similar to other chronic
pain conditions,29 chronic SCD pain is also associated
with comorbid psychiatric illness, most commonly major
depression and anxiety disorders.40,44,73,83

Dimension 4. Neurobiological,
Psychosocial, and Functional
Consequences of Chronic SCD Pain
Although not well characterized, the consequences
of chronic SCD pain likely include common psychosocial
and functional effects experienced by individuals with
other types of chronic pain, which are summarized in
Turk et al.75 In children and adolescents, acute SCD
pain is associated with increased impairment in daily activities such as school,28,64 having fewer friends, and
being less physically active.22 Reductions in healthrelated quality of life are well documented in adults21
and children with SCD pain, some of which was likely
chronic SCD pain.58 Activity restrictions because of
persistent pain are common in almost all chronic pain
disorders.45 Fatigue,2 somatic symptoms,71 and sleep
disturbances (including behavioral sleep problems,
sleep fragmentation, and increased risk for sleep disordered breathing and periodic limb movements46,76) are
common and associated with increased pain-related
disability in SCD adults, many of whom likely had
chronic SCD pain. For example, in one study of 328
adults with SCD, more than 70% had sleep disturbances, which were more common among those adults
with frequent SCD pain.81
Studies have shown that SCD disease complications are
associated with similar effects on function. Children and
adolescents with hip avascular necrosis have reduced
physical function of the affected hip1,18 and parents
report diminished global physical functioning.22 Similarly, adults with pain due to either hip avascular necrosis
or leg ulcers report effects on their physical functioning.21
Because SCD affects predominantly ethnic minorities
in the United States and there are substantial disparities
in wealth between white Americans and AfricanAmerican and Hispanic Americans,62 the relevance of socioeconomic conditions to pain, functioning, and
health-related quality of life is high in this population.
Lower family income and greater neighborhood socioeconomic distress have been associated with greater
pain-related functional disability in children with SCD
pain.37,57 Many people with SCD report experiences of
discrimination in health care encounters. The influence
of stigma and perceived discrimination on health
outcomes has been studied among individuals with
SCD, reporting associations between higher levels of
perceived disease stigma and discrimination and
increased clinical and laboratory pain and health care
utilization.7,49
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Dimension 5. Putative Neurobiological
and Psychosocial Mechanisms, Risk
Factors, and Protective Factors of Chronic
SCD Pain
Multiple mechanisms putatively underlie the experience of pain related to SCD including acute nociceptive
pain, inflammatory pain, neuropathic, and central pain
processes.8,23 It has been postulated that multiple
inputs including vaso-occlusive pain and chronic nociceptive pain as well as opioid-induced hyperalgesia from
chronic opioid therapy, cause central nervous system
sensitization leading to the evolution of chronic pain in
SCD.14,70 However, whether persistent pain represents
peripheral sensitization at the site(s) of tissue damage
and/or central sensitization has not been well studied in
humans with SCD. Similar to other chronic pain
syndromes in which central pain processing alterations
have been shown, individuals with SCD display several
features seen in centralized pain states, such as
widespread musculoskeletal pain and lower pain
thresholds on quantitative sensory testing to thermal
and mechanical stimuli compared with healthy control
participants,9,12,33,34,79 altered patterns of functional
connectivity of many brain regions,24 a lack of response
to opioid analgesia,3,85 and susceptibility to other pain
syndromes (ie, headache).55 Research interest has heightened in evaluating whether quantitative sensory testing
may predict clinical characteristics in patients with SCD
such as chronic pain (eg, Brandow and Panepinto,9 and
Campbell et al11,12).
In the absence of published diagnostic criteria, risk and
protective factors for chronic SCD pain have not yet been
identified. History of mental health diagnoses, somatization, and emotional factors are associated with higher
admission rates for vaso-occlusive pain in individuals with
SCD.54,74 In addition, poorer family functioning has been
related to increased health care utilization in children
with SCD.6 Similarly, in adults with patterns of frequent hospital utilization for pain management there was a 3-fold
higher prevalence of psychiatric illness in family members.15
These findings may be relevant to chronic SCD pain because
of their more frequent health care utilization.66

Chronic SCD Pain Diagnostic Modifiers
Three diagnostic modifiers indicate subtypes of chronic
SCD pain. The first modifier is labeled chronic SCD pain
without contributory disease complications. This modifier
is used if there is no evidence of contributory SCD complications on the basis of either clinical signs (eg, presence of
leg ulcers) or test results (eg, imaging abnormalities). For
example, a typical patient with this type of chronic SCD
pain may experience daily widespread musculoskeletal
pain. The second modifier is labeled chronic SCD pain
with contributory disease complications. This category
should be used if there is evidence of contributory SCD
complications on the basis of clinical signs or test results.
For example, a typical patient with this type of chronic
SCD pain may have persistent localized pain at the site
of a leg ulcer or bone injury. The third modifier is labeled
chronic SCD pain with mixed pain types. This category in-

dicates that there is evidence of contributory SCD complications (eg, avascular necrosis) on the basis of clinical signs
or test results and there is pain also occurring in unrelated
pain sites (eg, arms, back, chest, or abdominal pain, headache). For example, a typical patient with this type of
chronic SCD pain may have persistent pain in the hip due
to avascular necrosis but also experience unrelated persistent pain in the back, chest, and arms typical of their widespread musculoskeletal pain. Research is needed to
confirm and validate these modifiers and to develop specific strategies for assessment and management of chronic
pain that are tailored to each subtype.

Discussion
Chronic SCD pain is a serious complication associated
with increased morbidity and mortality, especially in
older adolescents and adults with SCD.38,60,61 Currently,
there is not a universally accepted classification system
for chronic SCD pain. A common set of diagnostic
criteria for classifying chronic SCD pain would improve
clinical assessment and management of this complex
condition. Indeed, recognition of chronic pain as a
distinct syndrome in SCD is a relatively new concept,
because of the historical focus on assessment and
management of acute vaso-occlusive pain. Over the
past several decades, a number of advances in medical
treatment of SCD (eg, prophylaxis against infection,
improved red cell transfusions, hydroxyurea therapy)
have led to improved life expectancy and most patients
with SCD live into at least middle adulthood. As patients
age, they accumulate tissue damage as disease-related
complications leading to an increasing frequency of
pain, which has likely led to a change in the symptom
experience of individuals with SCD over the decades. At
this time, it is critical to address chronic pain and its effect
on individuals with SCD.
Many studies have characterized individual complications of SCD, modeled after the SCD natural history studies
initiated in the late 1970s, but few studies have tried to
describe the co-occurrence of multiple SCD complications.
Thus the WG believed there was insufficient evidence to
currently support multiple diagnostic types of chronic
SCD pain. However, their clinical experience and available
literature did suggest that individuals with certain painful
SCD complications of significant duration, notably leg ulcers and avascular necrosis of hips/shoulders, could occur,
to varying degrees, in the absence of other more generalized SCD pain. Similarly, clinical experience and evolving
psychophysical9,10 and neuroimaging studies25 suggest
the existence of widespread/multifocal pain and overlapping pain disorders in individuals with SCD consistent with
central sensitization described in other chronic pain disorders.48 In this iteration of the AAPT taxonomy, the WG
chose to consider these likely subgroups as diagnostic
modifiers until the results of further validation studies
are available.
The WG suggested the frequency characteristic of ‘‘majority of days’’ for the chronic SCD pain definition corresponding to the 15 or more days per month used in the
chronic migraine definition in the International
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Classification of Headache Disorders. However, at this
time there are not adequate data to support this cutoff
in SCD or whether patterns of escalating pain frequency
are associated with the subsequent development of
chronic pain. An initial review of 3 years of daily pain
data from a study by Dampier et al21 suggests that this
cutoff may characterize recurrent episodic pain from
chronic pain in a small group of children with SCD but requires further study in larger samples. The consideration
of pain duration also was a difficult decision because few
longitudinal SCD pain studies were available to inform
this criterion. In the absence of appropriate data, a
6-month criterion was selected to be consistent with
that used by other AAPT WGs to define chronic pain.
Longer time durations may more effectively reduce misclassifying individuals with healing leg ulcers or avascular necrosis, and those with a self-limited period of
acute pain exacerbations, but will require further validation in SCD. A shorter duration may be more appropriate
in guiding treatment decisions, particularly in children.84
Future versions of the AAPT taxonomy will be updated to
provide more specific definitions of pain frequency and
duration when validation data are collected using these
diagnostic criteria in SCD.
Our WG applied a 5 axial system to identify critically
important aspects of chronic pain assessment and management in SCD, which calls attention to the evidence
gaps that exist in chronic SCD pain. The paucity of available research on chronic pain in SCD compared with
many other chronic pain disorders significantly limited
the WG’s ability to apply the AAPT dimensional framework. Because much of the SCD pain literature did not
make a distinction between frequent acute or persistent/chronic pain, the WG often relied on expert
consensus for domain characteristics. Indeed the Expert
Panel on Management of SCD84 also relied on consensus
in its guideline statement on chronic pain management
and relied on general literature on chronic pain rather
than evidence specifically related to chronic pain in individuals with SCD. However, the study by Sil et al,66 which
grouped children and adolescents with SCD using a pain
frequency classification similar to that proposed in this
report, observed only quantitative differences in several
functional outcomes and psychosocial characteristics between their chronic and episodic pain groups suggesting
that existing literature likely underestimates the effects
of chronic SCD pain.
Considerable research will be needed to provide evidence of the reliability and validity of the criteria proposed in this report for chronic SCD pain. This
iterative process has been extensively described in a
companion article and would involve field testing of
the criteria during clinical examinations of patients as
well as empirical studies of validity.10 Although we propose 3 diagnostic modifiers to indicate subtypes of
chronic SCD pain, at present there are few data that
describe the frequency of each of these subtypes of
pain, or whether the effect of chronic pain or prognosis
differ according to chronic pain subtype. Similarly, it
will be important to characterize the frequency and effects of acute recurrent vaso-occlusive pain in these
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chronic pain subtypes, because this is a particularly
difficult combination of pain syndromes to evaluate
and treat. Research is needed to distinguish between
the presence or absence of contributory disease complications as a source of chronic pain and to understand
the effect of chronic SCD pain subtypes on patient functioning and quality of life across the lifespan. Because
of the increase in SCD disease complications with age,
it is anticipated that developmental differences will
be found in the frequency of chronic pain subtypes,
highlighting the importance of considering normal
developmental processes that affect pain processing.80
Such studies would also likely identify the typical age
of onset for chronic pain. Moreover, it will be critical
to focus research attention on developing optimal
pain management strategies for individuals with
different chronic SCD pain subtypes, and for management of episodic acute pain (crises) in patients with
chronic SCD pain. Similarly, research is needed to identify disease management strategies that might reduce
the risk of developing chronic SCD pain or improve
the likelihood of its resolution.
There are several research priorities that were identified by our WG in applying an evidence-based chronic
pain taxonomy to SCD pain. First, we hope this taxonomy
will provide consistent criteria for conducting epidemiological studies of chronic pain prevalence and risk factors
for chronic pain in individuals with SCD across the lifespan. At present, epidemiological data are drawn from
a few key longitudinal diary studies, but larger sample
sizes are needed to test a broad range of biopsychosocial
risk factors for chronic SCD pain. Second, this taxonomy
may spark interest in studies of pain mechanisms in
SCD. Although it is clear that chronic SCD pain has multifactorial etiologies, at present there are limited available
data on any specific mechanisms to guide treatment decisions. Studies that better characterize chronic SCD pain
subtypes and phenotypes might elucidate different
mechanisms for pain associated with disease complications versus for chronic SCD pain unrelated to disease
complications. Third, therapeutic clinical trials in SCD
would also be facilitated by use of standard inclusion/
exclusion criteria for individuals with chronic SCD pain.
Previous studies have focused on identifying individuals
on the basis of frequency of health care utilization for
acute pain, likely producing heterogeneous samples. A
common set of diagnostic criteria for chronic SCD pain,
such as those presented in this report, can enhance the
conduct of clinical trials and lead to progress in development and testing of more effective therapies for SCD
pain management.
It is important to note that the appropriate use of this
classification is for evaluating chronic pain symptoms
among persons with SCD. It is not appropriate to use
this classification for classifying persons presenting
to the Emergency Department for management of
acute vaso-occlusive pain. Appropriate guidelines for
management of vaso-occlusive crisis pain are available
and should be followed.84 However, when patients present for follow-up care in the outpatient setting, this
classification may assist in planning the comprehensive
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care for the overall management of the patient’s pain
characteristics.

Conclusions
This WG synthesized available literature to provide evidence for the dimensions of a disease-specific
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